
NICE approve immunotherapy for adjuvant treatment of completely resected stage 3 melanoma
February 2021: NICE Recommends MSD’s KEYTRUDA® (pembrolizumab) for Routine Commissioning as Monotherapy for the Adjuvant Treatment of Adults with Stage III Melanoma with Lymph Node Involvement Who Have Undergone Complete Resection
Clinical Advances
Read more